A Study Shows No Benefits From The Finger-prick Blood Test (SMBG)
Patients with type 2 diabetes (T2D) think that the regular use of self-monitoring of blood glucose (SMBG) can keep their blood sugar level under control. The self-monitoring of blood glucose (SMBG) is a procedure which involves a finger-prick blood test to read blood sugar level from an instrument. The following are the expected benefits of self-monitoring of blood glucose (SMBG).
A study at the University of North Carolina, the United States shows no benefits to patients with type 2 diabetes (non-insulin-dependent) with a routine blood glucose testing (or the finger-prick blood test).
The researchers have conducted a study on 450 patients with type 2 (non-insulin-dependent) diabetes with an average age of 61 years to find out an improvement in hemoglobin A1c level and health-related quality of life (HRQOL). The self-monitoring of blood glucose (SMBG) is being followed by about 75 percent of patients. Duration of the study was one year.
The study shows no significant difference in health-related quality of life (HRQOL) and hemoglobin A1c level with the use of self-monitoring of blood glucose (SMBG). The study also shows no difference in the incidents of hospitalizations, emergency visits, low blood sugar level (or hypoglycemia) and instances of starting insulin therapy during the study period. No benefits of self-monitoring of blood glucose (SMBG) and the costs may outweigh the benefits.
The senior author of the study was Dr. Katrina Donahue, School of Medicine, the University of North Carolina, Chapel Hill, United States. The study was published in JAMA Internal Medicine. Title of the article is "Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial."
Aspirin May Cut The Risk Of Breast Cancer For Women Patients With Diabetes
Aspirin, an antiplatelet drug can lower the risk of cardiovascular diseases. An earlier study in 2012 shows that a 20 percent enhanced risk of breast cancer in women with diabetes.
A study at Chung Shan Medical University, Taichung City, Taiwan found a risk reduction to breast cancer for women patients with diabetes with long-term use of low-dose aspirin.
The researchers have done a 14 years follow-up study on 148,739 women patients of diabetes from the Taiwan National Health Insurance Research Database. They gave a low dose of aspirin (between 75 and 165 mg) daily to those participants. The follow-up study shows the following.
But the researchers have failed to find out the mechanism behind the reduction in the risk of breast cancer with low, medium or cumulative doses of aspirin.
The author of the study was Dr. Yi-Sun Yang, Chung Shan Medical University, Taichung, Taiwan. The study was published in the Journal of Women's Health. Title of the article is "Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.